Progestin-only oral contraception: A comprehensive review

McCann, Margaret F.; Potter, Linda S.

doi:10.1016/0010-7824(94)90114-7

Cited by 26 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Sixteen women were randomly allocated to take levonorgestrel pills or norethisterone pills 2-3 days before ovulation. 36 Cervical mucus quality and sperm contraceptive efficacy.…”

Section: Progestogen-only Pillsmentioning

confidence: 99%

“…Peak serum medroxyprogesterone acetate (MPA) concentrations are identified at 24 hours post-administration whilst peak concentrations following oral progestogen administration are at 1-2 hours. 35 The SPC for DMPA suggests administration in the first 5 days of the cycle without the need for condoms. 52 The SPC for NET-EN does not advise when during the menstrual cycle to start.…”

Section: Progestogen-only Injectablesmentioning

confidence: 99%

“…Unacceptable bleeding patterns are often given as a reason for discontinuation. 35 The etonogestrel-only implant is associated with abnormal bleeding: 20% of implant users will experience amenorrhoea, and up to 45% have infrequent, frequent or prolonged bleeding. Anovulation occurs throughout the 3 years' duration of use and therefore bleeding patterns are unlikely to change significantly with time.…”

Section: Progestogen-only Pills and Implantsmentioning

confidence: 99%

See 2 more Smart Citations

FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence

2005

j fam plann reprod health care

View full text Add to dashboard Cite

This Guidance provides information for clinicians and women considering the use of contraception outside the terms of the product licence. A key to the grades of recommendations, based on levels of evidence, is given at the end of this document. Details of the methods used by the Clinical Effectiveness Unit (CEU) in developing this Guidance and evidence tables summarising the research basis of the recommendations are available on the Faculty website (www.ffprhc.org.uk). Abbreviations (in alphabetical order) used include: CEU, Clinical Effectiveness Unit; COC, combined oral contraception/contraceptive; DMPA, depot medroxyprogesterone acetate; ENG, etonogestrel; IUD, copper-bearing intrauterine contraceptive device; LNG-IUS, levonorgestrel-releasing intrauterine system; NET-EN, norethisterone enantate; PGD, Patient Group Direction; PIL, Patient Information Leaflet; POC, progestogen-only contraception/contraceptive; POEC, progestogen-only emergency contraception; POP, progestogen-only pill; RCT, randomised controlled trial; SPC, Summary of Product Characteristics; UPSI, unprotected sexual intercourse; WHO, World Health Organization; WHOMEC, WHO Medical Eligibility Criteria for Contraceptive Use; WHOSPR, WHO Selected Practice Recommendations for Contraceptive Use.

show abstract

“…35 Sixteen women were randomly allocated to take levonorgestrel pills or norethisterone pills 2-3 days before ovulation. 36 Cervical mucus quality and sperm contraceptive efficacy.…”

Section: Progestogen-only Pillsmentioning

confidence: 99%

Section: Progestogen-only Injectablesmentioning

confidence: 99%

Section: Progestogen-only Pills and Implantsmentioning

confidence: 99%

See 1 more Smart Citation

FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence

2005

j fam plann reprod health care

View full text Add to dashboard Cite

show abstract

“…39 However, the efficacy is likely to be reduced as for other oral hormonal methods. Manufacturers of POPs do not recommend their continued used for women taking liver enzyme-inducing drugs.…”

Section: Progestogen-only Contraception (Poc)mentioning

confidence: 99%

FFPRHC Guidance (April 2005) Drug interactions with hormonal contraception

2005

j fam plann reprod health care

View full text Add to dashboard Cite

This Guidance provides information for clinicians and women using hormonal contraception applicable when concurrent medications are prescribed. A key to the grades of recommendations, based on levels of evidence, is given at the end of this document. Details of the methods used by the Clinical Effectiveness Unit (CEU) in developing this Guidance and evidence tables summarising the research basis of the recommendations are available on the Faculty website (www.ffprhc.org.uk). Abbreviations (in alphabetical order) used include:

show abstract

“…The contraceptive effect of POPs depends on their capacity to inhibit ovulation (which standard POPs do in around half of all cycles), delay ovum transport, thicken cervical mucus (making it hostile to sperm) and help to make the endometrium unreceptive to implantation 3. For women who opt for oral contraception, POPs are rarely a first choice because, as well as being less reliable than COCs, their use is associated with irregular vaginal bleeding patterns and requires keeping to a strict regimen (i.e.…”

Section: Introductionmentioning

confidence: 99%

Is Cerazette the minipill of choice?

2003

DTB

View full text Add to dashboard Cite

Around 5% of women aged 16-49 years in Great Britain use a progestogen-only pill (POP; 'minipill') as contraception.1 These pills are used as alternatives to combined oral contraceptives (COCs), compared to which they are less reliable at preventing pregnancy: the estimated contraceptive failure rate of POPs is 0.5 pregnancies per 100 woman-years when used consistently and correctly, compared with 0.1 per 100 woman-years for COCs.2 Cerazette (Organon), a new POP, is being promoted by the company as "the first oestrogen free pill to consistently inhibit ovulation", as having "the efficacy of a combined pill, with the reassurance of an oestrogen free pill" and offering "reliable contraception for women of any reproductive age". Here, we consider whether Cerazette offers advantages over established POPs.

show abstract

Progestin-only oral contraception: A comprehensive review

Cited by 26 publications

References 0 publications

FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence

FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence

FFPRHC Guidance (April 2005) Drug interactions with hormonal contraception

Is Cerazette the minipill of choice?

Contact Info

Product

Resources

About